Pliant stock rises as lung disease drug bexotegrast meets main goal of trial
designer491/iStock via Getty Images Pliant Therapeutics (NASDAQ:PLRX) said bexotegrast 320-mg dose met the main and secondary goals of a phase ...
designer491/iStock via Getty Images Pliant Therapeutics (NASDAQ:PLRX) said bexotegrast 320-mg dose met the main and secondary goals of a phase ...
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.